Safety, Tolerability and Pharmacodynamics of SYNB1020

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

July 19, 2019

Study Completion Date

July 19, 2019

Conditions
Cirrhosis
Interventions
DRUG

SYNB1020

SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

OTHER

Placebo

Subjects received placebo orally in a chilled buffered solution (100 mL).

Trial Locations (5)

23249

McGuire VA Medical Center, Richmond

29425

Medical University of South Carolina, Charleston

78006

Texas Liver Institute, San Antonio

92118

Southern California Research Center, Coronado

92377

Inland Empire Liver Foundation, Rialto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Synlogic

INDUSTRY

NCT03447730 - Safety, Tolerability and Pharmacodynamics of SYNB1020 | Biotech Hunter | Biotech Hunter